Breathe Well Live Well
 |
Related Articles |
Coronary spasm secondary to biphasic anaphylaxis after hymenoptera stings.
Ann Allergy Asthma Immunol. 2016 Jun 1;
Authors: Blasco-Navalpotro MÁ, Orejas-Gallego A, Flordelís-Lasierra JL, Prior-Gómez N, Jiménez-Jiménez J, Seoane-Leston FJ
PMID: 27263087 [PubMed – as supplied by publisher]
View full post on pubmed: asthma
Hypereosinophilic syndrome secondary to strongyloides infection: a case of recurrent asthma exacerbations.
BMJ Case Rep. 2013;2013
Authors: Khan WA, Santhanakrishnan K
Abstract
Hypereosinophilic syndrome is a disease characterised by a persistently elevated eosinophil count. The syndrome can be reactive to infections, autoimmune disease, cancers, etc. Multiple organ involvement can occur including cardiomyopathies, pulmonary involvement and neuropathies. We describe a case of a patient who presented with signs and symptoms of asthma with recurrent asthma exacerbations, but in fact proved to be hypereosinophilic syndrome secondary to strongyloides infection.
PMID: 23964035 [PubMed – in process]
View full post on pubmed: asthma
|
Array BioPharma: ARRY-502 Meets Primary And Secondary Endpoints In …
RTT News Array BioPharma Inc. (ARRY: Quote) announced positive results from a placebo-controlled, randomized, double-blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, an oral CRTh2 antagonist. ARRY-502 achieved the primary … |
View full post on asthma – Google News
|
ARRY-502 Meets Primary And Key Secondary Endpoints In Asthma Study
PR Newswire (press release) BOULDER, Colo., July 23, 2013 /PRNewswire/ — Array BioPharma Inc. (NASDAQ: ARRY) today announced positive results from a placebo-controlled, randomized, double?blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, … Array Biopharma To Report Top-line Results From ARRY-502 Asthma Trial After-market Movers For July 22 (NFLX, TXN, SANM, ARRY) |
View full post on asthma – Google News